Li, Zhijian http://orcid.org/0000-0003-1849-1672
Amaya, Laura http://orcid.org/0000-0002-8742-9111
Pi, Ruoxi http://orcid.org/0000-0002-2491-0979
Wang, Sean K. http://orcid.org/0000-0003-1557-8510
Ranjan, Alok http://orcid.org/0000-0001-9906-4044
Waymouth, Robert M. http://orcid.org/0000-0001-9862-9509
Blish, Catherine A. http://orcid.org/0000-0001-6946-7627
Chang, Howard Y. http://orcid.org/0000-0002-9459-4393
Wender, Paul A. http://orcid.org/0000-0001-6319-2829
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA245533-03)
Emerson Collective
Article History
Received: 26 January 2023
Accepted: 18 October 2023
First Online: 1 November 2023
Competing interests
: H.Y.C. is a co-founder of Accent Therapeutics, Boundless Bio, Cartography Biosciences, Orbital Therapeutics, and an advisor of 10x Genomics, Arsenal Biosciences, Chroma Medicine, and Spring Discovery. P.A.W. is a co-founder of BryoLogyx and N1 Life and an advisor to BryoLogyx, N1 Life, Synaptogenix, Cytokinetics, Evonik, SuperTrans Medical, Ativo, and Vault Pharma. R.M.W. is an advisor to Evonik. The remaining authors declare no competing interests. C.A.B. is a scientific advisory board member for Catamaran Bio, Immunebridge, and Qihan Ltd on topics unrelated to this study.